Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients

References

• Al-Samkari H, Connors JM. The role of direct oral anticoagulants in treatment of cancer-associated thrombosis. Cancers (Basel). 2018;10(8). doi:10.3390/cancers10110400
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. doi:10.1056/NEJMoa130250723808982
   PubMed Web of Science ®Google Scholar
• Investigators E, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–2510. doi:10.1056/NEJMoa101120521128814
   PubMed Web of Science ®Google Scholar
• Investigators E-P, Buller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–1297. doi:10.1056/NEJMoa111470522449293
   PubMed Web of Science ®Google Scholar
• Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352. doi:10.1056/NEJMoa090659819966341
   PubMed Web of Science ®Google Scholar
• Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406–1415. doi:10.1056/NEJMoa130663823991658
   PubMed Web of Science ®Google Scholar
• Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood. 2013;122(10):1712–1723. doi:10.1182/blood-2012-12-47102923908465
   PubMed Web of Science ®Google Scholar
• Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809–815. doi:10.1001/archinte.160.6.80910737280
   PubMed Web of Science ®Google Scholar
• Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715–722. doi:10.1001/jama.293.6.71515701913
   PubMed Web of Science ®Google Scholar
• Cronin-Fenton DP, Sondergaard F, Pedersen LA, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010;103(7):947–953. doi:10.1038/sj.bjc.660582220842120
   PubMed Web of Science ®Google Scholar
• Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013;49(6):1404–1413. doi:10.1016/j.ejca.2012.10.02123146958
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW. Risk prediction of cancer-associated thrombosis: appraising the first decade and developing the future. Thromb Res. 2018;164 Suppl 1:S70–S76. doi:10.1016/j.thromres.2018.01.03629395243
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632–634. doi:10.1111/j.1538-7836.2007.02374.x17319909
   PubMed Web of Science ®Google Scholar
• Sorensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846–1850. doi:10.1056/NEJM20001221343250411117976
   PubMed Web of Science ®Google Scholar
• Watson HG, Keeling DM, Laffan M, Tait RC, Makris M. British Committee for Standards in H. Guideline on aspects of cancer-related venous thrombosis. Br J Haematol. 2015;170(5):640–648. doi:10.1111/bjh.2015.170.issue-526114207
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Connors JM. Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulability. Am J Hematol. 2018;93(6):E156–E158. doi:10.1002/ajh.v93.629603336
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Werth S, Folprecht G, Weiss N. Trousseau’s syndrome in a patient with adenocarcinoma of unknown primary and therapy-resistant venous thrombosis treated with dabigatran and fondaparinux. Br J Clin Pharmacol. 2011;72(4):715–716. doi:10.1111/j.1365-2125.2011.03965.x21392076
   PubMed Web of Science ®Google Scholar
• Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100(10):3484–3488. doi:10.1182/blood-2002-03-070612393647
   PubMed Web of Science ®Google Scholar
• Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore). 1999;78(5):285–291. doi:10.1097/00005792-199909000-0000110499070
   PubMed Web of Science ®Google Scholar
• Monreal M, Falga C, Valdes M, et al. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost. 2006;4(9):1950–1956. doi:10.1111/j.1538-7836.2006.02117.x16961602
   PubMed Web of Science ®Google Scholar
• Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis? Am J Med. 2001;110(7):515–519.11343664
   PubMed Web of Science ®Google Scholar
• Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146–153. doi:10.1056/NEJMoa03096912853587
   PubMed Web of Science ®Google Scholar
• Patel HK, Khorana AA. Anticoagulation in cancer patients: a summary of pitfalls to avoid. Curr Oncol Rep. 2019;21(2):18. doi:10.1007/s11912-019-0767-530715628
   PubMed Web of Science ®Google Scholar
• Engman CA, Zacharski LR. Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patients. J Natl Compr Cancer Netw. 2008;6(7):637–645. doi:10.6004/jnccn.2008.0050
   PubMedGoogle Scholar
• Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56–70. doi:10.1111/jth.1207023217107
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e419S–e496S.22315268
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(17):2189–2204. doi:10.1200/JCO.2013.49.021923669224
   PubMed Web of Science ®Google Scholar
• Kahale LA, Hakoum MB, Tsolakian IG, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6:CD006650.29920657
   PubMed Web of Science ®Google Scholar
• Sobieraj DM, Baker WL, Smith E, et al. Anticoagulation for the treatment of cancer-associated thrombosis: a systematic review and network meta-analysis of randomized trials. Clin Appl Thromb Hemost. 2018 Sep 24:1076029618800792. doi:10.1177/1076029618800792.
   Google Scholar
• Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs Warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015;314(7):677–686. doi:10.1001/jama.2015.924326284719
   PubMed Web of Science ®Google Scholar
• Khorana AA, McCrae KR, Milentijevic D, et al. Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis. Res Pract Thromb Haemost. 2017;1(1):14–22. doi:10.1002/rth2.1200230046670
   PubMed Web of Science ®Google Scholar
• van Es N, Coppens M, Schulman S, Middeldorp S, Buller HR. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124(12):1968–1975. doi:10.1182/blood-2014-04-57123224963045
   PubMed Web of Science ®Google Scholar
• Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615–624. doi:10.1056/NEJMoa171194829231094
   PubMed Web of Science ®Google Scholar
• Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–2023. doi:10.1200/JCO.2018.78.803429746227
   PubMed Web of Science ®Google Scholar
• McBane RD, Wysokinski W, Le-Rademacher J, et al. Apixaban, Dalteparin, in active cancer associated venous thromboembolism, the ADAM VTE trial. San Diego, CA: 2018 Annual Meeting of the American Society for Hematology; December 2018.
   Google Scholar
• McBane R 2nd, Loprinzi CL, Ashrani A, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism. Thromb Haemost. 2017;117(10):1952–1961. doi:10.1160/TH17-03-0193
   PubMed Web of Science ®Google Scholar
• Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019 Jan;173:158–163. doi:10.1016/j.thromres.2018.02.144.
   Web of Science ®Google Scholar
• Rossel A, Robert-Ebadi H, Combescure C, et al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: a systematic review and network meta-analysis. PLoS One. 2019;14(3):e0213940. doi:10.1371/journal.pone.021394030897142
   PubMed Web of Science ®Google Scholar
• Elsebaie MAT, van Es N, Langston A, Buller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: a systematic review and meta-analysis. J Thromb Haemost. 2019;17(4):645–656. doi:10.1111/jth.1439830690830
   PubMed Web of Science ®Google Scholar
• Li A, Garcia DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis. Thromb Res. 2019;173:158–163. doi:10.1016/j.thromres.2018.02.14429506866
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa090556119717844
   PubMed Web of Science ®Google Scholar
• Desai J, Kolb JM, Weitz JI, Aisenberg J. Gastrointestinal bleeding with the new oral anticoagulants–defining the issues and the management strategies. Thromb Haemost. 2013;110(2):205–212. doi:10.1160/TH13-02-015023702623
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa100963821830957
   PubMed Web of Science ®Google Scholar
• Kraaijpoel N, Di Nisio M, Mulder FI, et al. Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer Study. Thromb Haemost. 2018;118(8):1439–1449. doi:10.1055/s-0038-166700130060256
   PubMed Web of Science ®Google Scholar
• Zakai NA, Walker RF, MacLehose RF, Adam TJ, Alonso A, Lutsey PL. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. J Thromb Haemost. 2018. doi:10.1111/jth.14303
   Web of Science ®Google Scholar
• Soff G, Sarasohn D, Haegler-Laube E, et al. Safe and effective use of rivaroxaban for treatment of cancer associated venous thromboembolic disease. San Diego, CA: 2018 Annual Meeting of the American Society for Hematology; December 2018..
   Google Scholar
• Agnelli G, Becattini C, Bauersachs R, et al. Apixaban versus Dalteparin for the treatment of acute venous thromboembolism in patients with cancer: the Caravaggio Study. Thromb Haemost. 2018;118(9):1668–1678. doi:10.1055/s-0038-166852330103252
   PubMed Web of Science ®Google Scholar
• Carney BJ, Uhlmann EJ, Puligandla M, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost. 2019;17(1):72–76. doi:10.1111/jth.1433630450803
   PubMed Web of Science ®Google Scholar
• Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018;16(9):1891–1894. doi:10.1111/jth.1421930027649
   PubMed Web of Science ®Google Scholar
• Soff GA. Use of direct oral anticoagulants for treating venous thromboembolism in patients with cancer. J Natl Compr Cancer Netw. 2018;16(5S):670–673. doi:10.6004/jnccn.2018.0041
   PubMedGoogle Scholar
• Riess H, Prandoni P, Harder S, Kreher S, Bauersachs R. Direct oral anticoagulants for the treatment of venous thromboembolism in cancer patients: potential for drug-drug interactions. Crit Rev Oncol Hematol. 2018;132:169–179. doi:10.1016/j.critrevonc.2018.09.01530447923
   PubMed Web of Science ®Google Scholar
• Hutchinson A, Rees S, Young A, Maraveyas A, Date K, Johnson MJ. Oral anticoagulation is preferable to injected, but only if it is safe and effective: an interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliat Med. 2019;33(5):510–517.
   Web of Science ®Google Scholar
• Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G. Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica. 2015;100(11):1486–1492. doi:10.3324/haematol.2015.12712626294737
   PubMed Web of Science ®Google Scholar
• Cimminiello C, Anderson FA Jr. Physician and patient perceptions of the route of administration of venous thromboembolism prophylaxis: results from an international survey. Thromb Res. 2012;129(2):139–145. doi:10.1016/j.thromres.2011.07.01721816454
   PubMed Web of Science ®Google Scholar
• Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452–e466. doi:10.1016/S1470-2045(16)30369-227733271
   PubMed Web of Science ®Google Scholar
• Elalamy I, Mahe I, Ageno W, Meyer G. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost. 2017;15(5):848–857. doi:10.1111/jth.1365928222250
   PubMed Web of Science ®Google Scholar
• Al-Samkari H, Connors JM. Anticoagulation and enzalutamide: caution over convenience. J Oncol Pract. 2017;13(11):728–729. doi:10.1200/JOP.2017.02766429125926
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511–520. doi:10.1056/NEJMoa150200026095746
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Milling TJ Jr, Eikelboom JW, et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131–1141. doi:10.1056/NEJMoa160788727573206
   PubMed Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2142. doi:10.1056/NEJMc141180025371966
   PubMed Web of Science ®Google Scholar
• Weber J, Olyaei A, Shatzel J. The efficacy and safety of direct oral anticoagulants in patients with chronic renal insufficiency: a review of the literature. Eur J Haematol. 2019;102(4):312–318. doi:10.1111/ejh.1320830592337
   PubMed Web of Science ®Google Scholar
• Kooiman J, Den Exter PL, Cannegieter SC, et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost. 2013;11(11):1968–1976. doi:10.1111/jth.1241124112123
   PubMed Web of Science ®Google Scholar
• Lyman GH, Bohlke K, Falanga A; American Society of Clinical O. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract. 2015;11(3):e442–444. doi:10.1200/JOP.2015.00447325873061
   PubMed Web of Science ®Google Scholar
• Wang T-F, Li A, Garcia D. Managing thrombosis in cancer patients. Res Pract Thromb Haemost. 2018;2(3):429–438. doi:10.1002/rth2.1210230046747
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer. 2007;110(10):2339–2346. doi:10.1002/cncr.2306217918266
   PubMed Web of Science ®Google Scholar
• Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007;25(34):5490–5505. doi:10.1200/JCO.2007.14.128317968019
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902–4907. doi:10.1182/blood-2007-10-11632718216292
   PubMed Web of Science ®Google Scholar
• Khorana AA, Kamphuisen PW, Meyer G, et al. Tissue factor as a predictor of recurrent venous thromboembolism in malignancy: biomarker analyses of the CATCH trial. J Clin Oncol. 2017;35(10):1078–1085. doi:10.1200/JCO.2016.67.456428029329
   PubMed Web of Science ®Google Scholar
• Khorana AA, Rao MV. Approaches to risk-stratifying cancer patients for venous thromboembolism. Thromb Res. 2007;120 Suppl 2:S41–S50. doi:10.1016/S0049-3848(07)70129-918023712
   PubMed Web of Science ®Google Scholar
• Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008;112(7):2703–2708. doi:10.1182/blood-2008-02-14242218539899
   PubMed Web of Science ®Google Scholar
• Pabinger I, van Es N, Heinze G, et al. A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol. 2018;5(7):e289–e298. doi:10.1016/S2352-3026(18)30063-229885940
   PubMed Web of Science ®Google Scholar
• Parker A, Peterson E, Lee AYY, et al. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer. J Thromb Haemost. 2018;16(7):1321–1326. doi:10.1111/jth.1413929733498
   PubMed Web of Science ®Google Scholar
• Patell R, Rybicki L, McCrae KR, Khorana AA. Predicting risk of venous thromboembolism in hospitalized cancer patients: utility of a risk assessment tool. Am J Hematol. 2017;92(6):501–507. doi:10.1002/ajh.2470028240823
   PubMed Web of Science ®Google Scholar
• Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7(3):291–292. doi:10.1007/s11739-012-0784-y22547369
   PubMed Web of Science ®Google Scholar
• Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116(24):5377–5382. doi:10.1182/blood-2010-02-27011620829374
   PubMed Web of Science ®Google Scholar
• Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–719. doi:10.1056/NEJMoa181446830511879
   PubMed Web of Science ®Google Scholar
• Khorana AA, Soff GA, Kakkar AK, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380(8):720–728. doi:10.1056/NEJMoa181463030786186
   PubMed Web of Science ®Google Scholar
• Pollack CV Jr., Bernstein R, Dubiel R, et al. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD study. J Med Econ. 2017;20(5):435–442. doi:10.1080/13696998.2016.127322927981865
   PubMed Web of Science ®Google Scholar
• Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699–708. doi:10.1056/NEJMoa120754123216615
   PubMed Web of Science ®Google Scholar
• Streiff MB, Holmstrom B, Angelini D, et al. NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018. J Natl Compr Cancer Netw. 2018;16(11):1289–1303. doi:10.6004/jnccn.2018.0084
   PubMed Web of Science ®Google Scholar
• Francis CW, Kessler CM, Goldhaber SZ, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost. 2015;13(6):1028–1035. doi:10.1111/jth.1292325827941
   PubMed Web of Science ®Google Scholar
• Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T, et al. Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res. 2017;157:90–96. doi:10.1016/j.thromres.2017.07.00428719850
   PubMed Web of Science ®Google Scholar
• Streiff MB, Milentijevic D, McCrae K, et al. Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer. Am J Hematol. 2018;93(5):664–671. doi:10.1002/ajh.2505929396864
   PubMed Web of Science ®Google Scholar
• Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729–1735.12153376
   PubMed Web of Science ®Google Scholar
• Lee AY, Rickles FR, Julian JA, et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005;23(10):2123–2129. doi:10.1200/JCO.2005.03.13315699480
   PubMed Web of Science ®Google Scholar
• Deitcher SR, Kessler CM, Merli G, et al. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389–396. doi:10.1177/107602960629369217000884
   PubMed Web of Science ®Google Scholar
• Hull RD, Pineo GF, Brant RF, et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062–1072. doi:10.1016/j.amjmed.2006.02.02217145251
   PubMed Web of Science ®Google Scholar
• Carrier M, Le Gal G, Cho R, Tierney S, Rodger M, Lee AY. Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients. J Thromb Haemost. 2009;7(5):760–765. doi:10.1111/j.1538-7836.2009.03326.x19245418
   PubMed Web of Science ®Google Scholar
• Ihaddadene R, Le Gal G, Delluc A, Carrier M. Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. Thromb Res. 2014;134(1):93–95. doi:10.1016/j.thromres.2014.04.02824835673
   PubMed Web of Science ®Google Scholar
• Schulman S, Zondag M, Linkins L, et al. Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short-term prognosis. J Thromb Haemost. 2015;13(6):1010–1018. doi:10.1111/jth.1295525851122
   PubMed Web of Science ®Google Scholar
• Marshall AL, Campigotto F, Neuberg D, Rowe B, Connors JM. Recurrence of venous thromboembolism in patients with cancer treated with Warfarin. Clin Appl Thromb Hemost. 2015;21(7):632–638. doi:10.1177/107602961557909925850917
   PubMed Web of Science ®Google Scholar
• Tittl L, Endig S, Marten S, Reitter A, Beyer-Westendorf I, Beyer-Westendorf J. Impact of BMI on clinical outcomes of NOAC therapy in daily care - Results of the prospective Dresden NOAC Registry (NCT01588119). Int J Cardiol. 2018;262:85–91. doi:10.1016/j.ijcard.2018.03.06029622509
   PubMed Web of Science ®Google Scholar